Diagnostic retinal biopsy in the management of secondary non-CNS vitreoretinal lymphoma masquerading as viral retinitis: a case report

Aditya Rali1, Lucy T. Xu1, Caroline Craven1, Jonathon B. Cohen2, Steven Yeh1,3, Hans E. Grossniklaus1 and Ghazala D. O’Keefe1,4*

Abstract

Background: Intraocular lymphoma accounts for fewer than 1% of intraocular tumors. When the posterior segment is involved, it can be further classified as vitreoretinal or choroidal lymphoma. Vitreoretinal lymphoma (VRL) can rarely masquerade as an infectious retinitis making diagnosis and management challenging.

Results: A 73-year-old woman with a history of non-central nervous system (CNS) involving diffuse large B-cell lymphoma (DLBCL) was referred for worsening blurry vision—visual acuity of count figures at 2 ft—in her right eye for 8 months. Dilated fundus examination of the right eye was significant for retinal whitening and dot-blot hemorrhages, which was concerning for a viral retinitis and guided initial management. Secondary intraocular lymphoma was also considered. The retinal disease continued to progress despite intravitreal and systemic antiviral therapy, and a diagnostic vitrectomy was inconclusive. A retinal biopsy was then performed, which showed DLBCL, confirming a diagnosis of secondary VRL. Three subsequent treatments with intravitreal methotrexate led to regression of the VRL.

Conclusions: Our case highlights the utility of a retinal biopsy after an inconclusive diagnostic vitrectomy in a challenging scenario of VRL to establish a diagnosis and initiate successful treatment. A multidisciplinary team of providers was essential for diagnosis, comprehensive workup, medical and surgical management of the patient.

Keywords: Lymphoma, Large B-Cell, Diffuse, Intraocular lymphoma, Retina, Biopsy, Vitreoretinal surgery, Vitrectomy, Retinitis

Background

Intraocular lymphoma accounts for fewer than 1% of intraocular tumors [1]. When the posterior segment is involved, it can be further classified as vitreoretinal or choroidal lymphoma. Previous case reports have highlighted that vitreoretinal lymphoma (VRL) can rarely masquerade as an infectious retinitis making diagnosis and management challenging [2–5]. We describe a case of secondary VRL in a patient with a history of diffuse large B-cell lymphoma (DLBCL) that mimicked a viral retinitis during the patient’s initial presentation. Retinal biopsy was eventually required to achieve a pathologic diagnosis that guided management with intravitreal methotrexate therapy.
Case presentation
A 73-year-old woman with a history of non-central nervous system (CNS) involving DLBCL was referred for worsening blurry vision in her right eye for 8 months. Her DLBCL was initially diagnosed three years prior when she developed a neck mass and further imaging showed widespread adenopathy, splenomegaly and large right pleural effusion. More recently, she had been followed by an outside retina specialist and had received 6 intravitreal ganciclovir injections in the right eye along with oral valganciclovir for presumed CMV retinitis. Her ocular history was also remarkable for primary open angle glaucoma, affecting the left more than the right eye. Best corrected visual acuity was counting fingers at 2 ft in the right and 20/500 in left eye. The vision loss in the left eye was secondary to severe primary open angle glaucoma. Anterior segment examination of the right eye showed inferior keratic precipitates and trace cell and flare, while the left eye was unremarkable. Dilated fundus examination of the right eye showed 1+ anterior vitreous cell, mild vitreous haze, 0.5 cup-to-disc ratio with sharp rims, scattered areas of retinal whitening, most pronounced along vasculature, and diffuse dot blot hemorrhages and chorioretinal scars peripherally (Fig. 1a). Dilated fundus examination of the left eye showed 0.9 cup-to-disc with pallor and few temporal dot blot hemes (Fig. 2). Due to the ongoing suspicion for infectious retinitis, she was initially treated with intravitreal foscarnet and continued on oral valganciclovir. An anterior chamber paracentesis was negative for cytomegalovirus, herpes simplex virus, varicella zoster virus and toxoplasmosis by polymerase chain reaction testing.

Secondary intraocular lymphoma was also considered due to subjective visual changes following the identification of a local gastro-hepatic recurrence of DLBCL 3 years prior. The patient was referred to other specialties including neurology, hematology, and gastroenterology for further evaluation and treatment. The case was discussed at a multidisciplinary meeting with an ophthalmologist, hematologist, and neurologist.

The patient was scheduled for a second opinion from a medical oncologist. A lymphoma specialist was also consulted to evaluate for secondary intraocular lymphoma. Further management decisions would be made based on the results of the additional evaluations.
months prior to presentation to our service. Following the negative aqueous humor testing for herpetic viruses, a diagnostic vitrectomy was performed. Bacterial cultures and viral PCRs were negative, and cytopathology revealed non-specific chronic inflammation with proteinaceous material. Her visual acuity subjectively declined with progressive disease including new areas of retinal whitening and intraretinal hemorrhages (Fig. 1b, c).

The patient initially deferred further surgery, but due to clinical progression, a diagnostic retinal biopsy was performed (Additional file 1: Video S1). During standard 23-gauge vitrectomy, endodiathermy was used to mark the retinal biopsy site in the superonasal quadrant involving both normal and abnormal-appearing retina. Retinal scissors were used to incise the retina along the diathermized outline and internal limiting membrane (ILM) forceps were used to elevate the retinal tissue from the RPE. The superotemporal sclerotomy site was enlarged so the retinal biopsy could be extracted. Endolaser was applied to the edge of the retinal biopsy site followed by air-fluid exchange and 14% C3F8 instillation. Pathology was consistent with diffuse large B-cell lymphoma, confirming a diagnosis of secondary VRL (Fig. 3). Systemic workup, including a PET scan and MRI brain/orbits, did not show evidence of systemic DLBCL recurrence. The patient was subsequently treated with monthly intravitreal methotrexate 400 mcg/0.1 mL for 3 months with regression of the VRL and no evidence of recurrence over the 6-month follow-up period (Fig. 1d).

Discussion and conclusions
While non-CNS lymphoma has a much stronger predilection for the choroid than the retina [2, 6], our case was notable given its primary involvement of the retina. The clinical disease findings mimicked an infectious retinitis, making the diagnosis particularly challenging. Polymerase chain reaction testing is highly sensitive for DNA viruses [7] and negative PCR testing from the aqueous humor and vitreous obtained from the vitrectomy procedure raised our suspicion that the patient’s findings could indeed represent secondary lymphoma masquerading as an infectious retinitis. Previous reports have highlighted intraocular lymphoma masquerading as infectious retinitis, but only Say et al. utilized a retinal biopsy to confirm the diagnosis [3–6].

The retinal biopsy required close communication preoperatively with the Ophthalmic Pathology team and intraoperatively, we ensured meticulous hemostasis and controlled enlargement of the sclerotomy when the retinal biopsy was extracted. These steps were important to maintain visualization of the retinal biopsy and prevent the retinal tissue from falling posteriorly at the time of extraction. Given that there was no obvious subretinal fluid around the biopsy site, we also pre-placed endolaser prior to the air-fluid exchange in the event that the view became cloudy during the air-fluid exchange which could have precluded adequate endolaser.

In deciding on the medication regimen for the patient, our Retina and Uveitis service worked closely with the Hematology-Oncology service for the patient’s medical workup, which showed no evidence of active, systemic lymphoma. Thus, we elected to proceed with intravitreal methotrexate on a monthly basis with close monitoring of treatment response. We recently reviewed our experience with monthly intravitreal methotrexate injections and found that the majority of patients who received monthly intravitreal methotrexate injections avoided relapse and achieved partial or complete remission with a mean treatment duration of approximately 60 days [8]. Patients in that series also showed mean improvement in visual acuity [8]. In this case, monthly intravitreal methotrexate for a series of three doses led to disease regression at final follow-up. Indeed, prior case reports and series have successfully used methotrexate for intraocular

![Fig. 3](image-url)
lymphoma without serious adverse reactions although keratopathy has been reported [9, 10].

In summary, our case report describes a challenging case of secondary intraocular lymphoma that presented with clinical findings suggestive of viral retinitis. A retinal biopsy was essential to establish a pathologic diagnosis following an inconclusive diagnostic vitrectomy and informed ongoing patient management in conjunction with a multidisciplinary team of providers.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s40942-021-00327-3.

Acknowledgements

Not applicable.

Authors' contributions

AR conducted the literature review, played a key role in synthesizing the case report and preparing the manuscript. LX provided an edited surgical video and was a contributor in writing the manuscript. CC provided the histological figures and helped analyze the histology. JC provided the hematology and oncology side of the patient’s story and helped in revising the manuscript. HG played a key role in design and analysis of the case report, along with revising the manuscript. All authors read and approved the final manuscript.

Funding

This project was supported by unrestricted departmental grant from Research to Prevent Blindness, Inc. to the Emory Eye Center, Emory University School of Medicine, National Eye Institute/ National Institutes of Health core grant P30-EY06360 (Department of Ophthalmology, Emory University School of Medicine), National Eye Institute of the National Institutes of Health under award number R01 EY029594 (SY), and the Stanley M. Truhlsen Family Foundation, Inc. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent for participation

This case report was conducted in accordance with the Declaration of Helsinki. The collection and evaluation of all protected patient health information was performed in a Health Insurance Portability and Accountability Act (HIPAA)-compliant manner. This case report was part of an Emory IRB that approved retrospective chart review and provided an exemption for informed consent.

Consent for publication

This case report was part of an Emory IRB that approved retrospective chart review and provided an exemption for informed consent. This case report also does not include identifiable information in the form of text, images, or video.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Department of Ophthalmology, Emory University School of Medicine, Atlanta, GA, USA. 2 Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA. 3 Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE, USA. 4 Uveitis and Retinal Disease, Emory Eye Center, Emory University School of Medicine, Atlanta, USA.

Received: 7 May 2021 Accepted: 12 September 2021

Published online: 11 October 2021

References

1. Mochizuki M, Singh AD. Epidemiology and clinical features of intraocular lymphoma. Ocul Immunol Inflamm. 2009;17(2):69–72. https://doi.org/10.1080/09273940902957305.
2. Reddy V, Winslow R, Cao JH, Robertson ZM, Chen B, Ufret-Vincenty RL. Vitreoretinal lymphoma, secondary to non-CNS systemic lymphoma, masquerading as an infectious retinitis. Am J Ophthalmol Case Rep. 2019;16.
3. Ryan ME, Shantha JG, Grossniklaus HE, Yeh S. Secondary vitreoretinal lymphoma masquerading as acute retinal necrosis. Ophthalmic Surg Lasers Imaging Retina. 2015;46(10):1048–50. https://doi.org/10.3928/23258160-20151027-11.
4. Zloto O, Elkader AE, Fabian ID, Vishnevskia-Dai V. Primary vitreoretinal lymphoma masquerading as refractory retinitis. Case Rep Ophthalmol. 2015;6(3):345–50. https://doi.org/10.1159/000440762.
5. Say EA, Knupp CL, Gertzsch KR, Chavala SH. Metastatic B-cell lymphoma masquerading as infectious retinitis and vasculitis. Oncol Lett. 2012;3(6):1245–8. https://doi.org/10.3892/ol.2012.659 (Epub 2012 Mar 27).
6. Coupland SE, Damato B. Understanding intraocular lymphomas. Clin Exp Ophthalmol. 2008;36(6):564–78. https://doi.org/10.1111/j.1442-9071.2008.01843.x.
7. Harper TW, Miller D, Schiffman JC, Davis JL. Polymerase chain reaction analysis of aqueous and vitreous specimens in the diagnosis of posterior segment infectious uveitis. Am J Ophthalmol. 2009;147(1):140-7.e2. https://doi.org/10.1016/j.ajo.2008.07.043 (Epub 2008 Oct 2).
8. Anthony C, Bavinger C, Shantha J, Voloschin A, O’Keefe G, Grossniklaus H, Yeh S. Clinical outcomes following intravitreal methotrexate therapy for vitreoretinal lymphoma. Invest Ophthalmol Vis Sci. 2015;56(2):3306.
9. Frenkel S, Hendler K, Siegal T, Shalom E, Peer J. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience. Br J Ophthalmol. 2008;92(3):383–8. https://doi.org/10.1136/bjo.2007.127928.
10. Zhou X, Zhou X, Shi H, Lai J, Wang Q, Li Y, Chen K, Li Q, Zhou Q, Cao X, Chen B, Xiao J. Reduced frequency of Intravitreal methotrexate injection lowers the risk of keratopathy in vitreoretinal lymphoma patients. BMC Ophthalmol. 2020;20(1):189. https://doi.org/10.1186/s12886-020-01464-3.